Teva Pharmaceutical Industries Limited
Last updated September 27, 2026
Organization details
- Legal name
- Teva Pharmaceutical Industries Limited
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Israel
- Headquarters city
- TEL Aviv
- Headquarters country
- Israel
- Fiscal year end
- December
- Ticker symbol
- TEVA
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0000818686
Board of directors
-
Amir Elstein · DirectorSince 2023
-
Chen Lichtenstein · DirectorSince 2024
-
Gerald M. Lieberman · DirectorSince 2023
-
Janet S. Vergis · DirectorSince 2023
-
Perry Nisen · DirectorSince 2023
-
Roberto Mignone · DirectorSince 2023
-
Ronit Satchi-Fainaro · DirectorSince 2023
-
Rosemary A. Crane · DirectorSince 2023
-
Sol J. Barer · DirectorSince 2023
-
Tal Zvi Zaks · DirectorSince 2023
-
Varda Shalev · DirectorSince 2023
Director election results
Annual meeting of May 28, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
71.9%
Board connections
5 of this board's directors also sit on 7 other boards.
- via Rosemary A. Crane
- via Janet S. Vergis
- via Janet S. Vergis
- via Gerald M. Lieberman
- via Roberto Mignone
- via Rosemary A. Crane
- via Amir Elstein
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $113,291,830
- 58 sales by 14 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 18, 2026 | Roberto Mignone Director | Open-market sale | −367,600 | $39.06 | $14,356,802 |
| Sep 18, 2026 | Savage Brian Officer (Interim Chief Legal Officer) | Option exercise | +4,503 | $34.70 | $156,254 |
| Sep 18, 2026 | Savage Brian Officer (Interim Chief Legal Officer) | Open-market sale | −4,503 | $38.69 | $174,221 |
| Sep 18, 2026 | Savage Brian Officer (Interim Chief Legal Officer) | Open-market sale | −2,525 | $39.15 | $98,841 |
| Sep 18, 2026 | Savage Brian Officer (Interim Chief Legal Officer) | Open-market sale | −314 | $38.70 | $12,153 |
| Aug 21, 2026 | Ronit Satchi-Fainaro Director | Open-market sale | −415 | $37.25 | $15,459 |
| Aug 21, 2026 | Weiss Amir Officer (Chief Accounting Officer) | Open-market sale | −6,945 | $37.61 | $261,224 |
| Aug 21, 2026 | Weiss Amir Officer (Chief Accounting Officer) | Option exercise | +2,500 | $19.61 | $49,025 |
| Aug 21, 2026 | Weiss Amir Officer (Chief Accounting Officer) | Open-market sale | −2,500 | $37.63 | $94,077 |
| Aug 17, 2026 | Lippman Evan Officer (EVP, Business Development) | Open-market sale | −18,600 | $36.57 | $680,291 |
| Aug 5, 2026 | Tal Zvi Zaks Director | Open-market sale | −17 | $34.87 | $593 |
| Aug 3, 2026 | Eric A. Hughes Officer (See "Remarks") | Option exercise | +52,744 | — | — |
| Aug 3, 2026 | Jover Placid Officer (See "Remarks") | Option exercise | +12,827 | — | — |
| Aug 3, 2026 | Eric A. Hughes Officer (See "Remarks") | Open-market sale | −25,578 | $34.88 | $892,051 |
| Aug 3, 2026 | Jover Placid Officer (See "Remarks") | Open-market sale | −12,827 | $34.88 | $447,351 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.